(Reuters) - U.S. health regulators on Monday approved Roche's pill to treat an advanced form of the most common form of skin cancer, known as basal cell carcinoma. The drug, Erivedge, which was co-developed by Curis Inc, was given a green light by the Food and Drug Administration more than a month ahead of the expected March 8 decision date. It was approved for use by adults whose cancer cannot ...